# Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablet (ODT) And 10 Mg Amlodipine Besylate Tablets

> **NCT01138826** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Amlodipine - reference
- **DRUG:** Amlodipine ODT - test
- **DRUG:** Amlodipine ODT - test

## Key facts

- **NCT ID:** NCT01138826
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138826, "Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablet (ODT) And 10 Mg Amlodipine Besylate Tablets". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT01138826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*